奈莫利珠单抗联合外用药物治疗特应性皮炎(AD)伴中重度瘙痒患者,瘙痒和AD体征改善可持续至68周:两项III期长期研究结果
两项III期长期研究评估奈莫利珠单抗60 mg每4周皮下注射联合外用药物治疗≥13岁特应性皮炎伴中重度瘙痒患者。Study-JP01中奈莫利珠单抗/奈莫利珠单抗组从治疗开始至第68周瘙痒视觉模拟评分下降66%,湿疹面积和严重度指数下降78%,生活质量改善并维持,安全性特征与既往研究一致。
要点
- 奈莫利珠单抗60 mg每4周联合外用药物,瘙痒视觉模拟评分至第68周下降66%。
- 湿疹面积和严重度指数至第68周下降78%,生活质量指标在首次给药后改善并维持。
- 长期安全性特征与既往研究一致,未出现非预期迟发性不良事件。
核心结论
- 奈莫利珠单抗60 mg每4周联合外用药物可使特应性皮炎伴中重度瘙痒患者的瘙痒、AD体征和生活质量持续改善至68周,安全性良好。
研究设计与样本
- 两项III期长期研究:Study-JP01先双盲接受奈莫利珠单抗或安慰剂16周,后进入52周延长期均接受奈莫利珠单抗;Study-JP02接受奈莫利珠单抗52周;两项研究均含8周随访期。
- Study-JP01奈莫利珠单抗/奈莫利珠单抗组143例、安慰剂/奈莫利珠单抗组72例,Study-JP02奈莫利珠单抗组88例。
主要发现
- Study-JP01奈莫利珠单抗/奈莫利珠单抗组从治疗开始至第68周瘙痒视觉模拟评分下降66%,湿疹面积和严重度指数下降78%。
- 生活质量指标在首次奈莫利珠单抗给药后改善,并在随访期内维持。
- 长期安全性特征与既往研究一致,未出现非预期迟发性不良事件。
关键数值与推荐
- 奈莫利珠单抗60 mg每4周皮下注射,联合外用治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin (IL)-31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration period. OBJECTIVES: To examine the long-term effectiveness and safety of nemolizumab in patients aged ≥ 13 years with AD and inadequately controlled moderate-to-severe pruritus. METHODS: In two long-term phase III studies, nemolizumab 60 mg every 4 weeks (Q4W) was administered subcutaneously, concomitantly with topical treatments. Study-JP01 patients received double-blind nemolizumab or placebo for 16 weeks, and then entered a 52-week extension period in which all patients received nemolizumab (nemolizumab/nemolizumab and placebo/nemolizumab groups). Study-JP02 patients received nemolizumab for 52 weeks. Both studies included an 8-week follow-up period. RESULTS: Study-JP01 nemolizumab/nemolizumab and placebo/nemolizumab, and Study-JP02 nemolizumab groups comprised 143, 72 and 88 patients, respectively. In the nemolizumab/nemolizumab group, there were clinically meaningful improvements from the start of treatment to week 68 in the pruritus visual analogue scale (66% decrease) and Eczema Area and Severity Index (78% decrease). Quality of life (QoL) indicators improved after the first nemolizumab dose; improvements were maintained during the follow-up period. The long-term safety profile was consistent with previous studies, with no unexpected late-onset adverse events. CONCLUSIONS: Nemolizumab 60 mg Q4W with concomitant topical treatments in patients with AD and inadequately controlled moderate-to-severe pruritus produced a continuous improvement in pruritus, signs of AD, and QoL for up to 68 weeks, with a favourable safety profile.
引用
- Kabashima K, Matsumura T, Komazaki H, et al. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol. 2021. PMID: 34726262. doi:10.1111/bjd.20873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。